| Patient | Booker T. Washington |
|---|---|
| Date of birth | 1967-04-05 |
| Identifiers | MRN HR-NI017-SYN; SSN (made up) 000-17-2284 |
| Document date | 2026-06-29 |
| Author | Lorraine Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week check after adding chlorthalidone. [S]
Mr. Washington returns four weeks after chlorthalidone was added. His home readings run in the 120s and low 130s over 70s and 80s. He has had no headaches for six weeks, and his concentration is a little better. He has had no lightheadedness on standing, muscle cramps, or joint pain, and he takes all five medicines every morning from a weekly organizer. He still gets up once or twice a night to urinate. [S]
| Element | Detail |
|---|---|
| Home blood pressure | 120s to low 130s over 70s to 80s |
| Symptoms | No headaches for six weeks; concentration a little better |
| Medication tolerance | No lightheadedness, cramps, or joint pain on chlorthalidone |
| Adherence | Weekly organizer; every dose taken |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; weight stable |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Musculoskeletal | Negative | No cramps or joint pain |
| Genitourinary | Positive | Up once or twice a night to urinate; no dysuria |
| Neurological | Negative | No headache or lightheadedness on standing |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily | One-half tablet by mouth daily | Oral route | 2026-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-29 | Body height | 170 | cm | S |
| 2026-06-29 | Body weight | 70 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 74 | /min | S |
| 2026-06-29 | Respiratory rate | 14 | /min | S |
| 2026-06-29 | Body temperature | 36.7 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-29 | Sodium [Moles/volume] in Serum or Plasma | 135 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-29 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-06-29 | Urea nitrogen [Mass/volume] in Serum or Plasma | 36 | mg/dL | 6-24 mg/dL | High | S |
| 2026-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 30 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-06-29 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-29 | Albumin/Creatinine [Mass Ratio] in Urine | 360 | mg/g | <=30 mg/g | High | S |
Vital signs recorded on 2026-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Blood pressure | 128/80 mmHg, the average of two seated readings after five minutes' rest; no fall on standing |
| Heart | Regular rhythm, rate 74; soft S4 |
| Lungs | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150 | active | confirmed | I12.9 | S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R. |
| Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis | active | confirmed | N18.32 | S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease. |
| Hypertensive retinopathy, both eyes, without papilledema | active | confirmed | H35.033 | S — Synthetic funduscopic finding that echoes the documented failing vision. |
| Mild anemia of chronic kidney disease, iron replete; monitor | active | confirmed | D63.1 | S — Synthetic finding from the baseline hemoglobin and iron studies. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine (basic metabolic panel) | 2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR draw | Completed today | Four weeks after starting chlorthalidone. Potassium 4.3, sodium 135 (low-normal), creatinine 2.4 mg/dL, eGFR 30: stable |
| Laboratory | Urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Completed today | 360 mg/g, down 56 percent from 820; still A3 |
| Laboratory | eGFR and urine albumin, next pair | About 3 times a year for G3b A3 | Due | Next at the six-month review, in about four months |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months in G3b | Due | At the six-month review |
| Laboratory | 25-hydroxyvitamin D | Once at baseline | Due | Planned with the six-month calcium, phosphate, and PTH |
| Laboratory | Hemoglobin | At least yearly in G3 | Due | At the six-month review |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5 | Due | At the six-month review |
| Laboratory | Lipid panel | Once at diagnosis in chronic kidney disease; 4 to 12 weeks after a statin start in the lipid monograph | Not indicated | LDL 138 mg/dL at diagnosis. The CKD monograph and KDIGO advise against routine follow-up LDL testing once a statin is started, and the care plan follows them; this departs by choice from the lipid monograph's 4 to 12 week panel, whose window is now open |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 128/80 mmHg; below 130/80 but above the systolic target of 120 |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 70 kg; soft S4 |
| Medication safety | Chlorthalidone safety | Each visit while starting | Completed today | Sodium 135 and potassium 4.3; no orthostatic fall, cramps, or gout |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs; doses checked for eGFR 30 |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Completed today | Hepatitis B vaccine dose 2 today; influenza vaccine due in the fall |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Home log reviewed; walking most days |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)
Follow-up: Preventive visit in September. Six-month blood pressure and kidney review with eGFR, urine albumin, hemoglobin, calcium, phosphate, PTH, vitamin D, and the kidney failure risk. Next scheduled visit 2026-09-21: periodic adult preventive visit. [S]